5α‐Reductase inhibitors and prostatic disease
1994; Wiley; Volume: 41; Issue: 2 Linguagem: Inglês
10.1111/j.1365-2265.1994.tb02521.x
ISSN1365-2265
Autores Tópico(s)Prostate Cancer Treatment and Research
ResumoClinical EndocrinologyVolume 41, Issue 2 p. 139-147 Free Access 5α-Reductase inhibitors and prostatic disease Fritz H. Schröder, Corresponding Author Fritz H. SchröderProfessor Fritz H. Schröder, Department of Urology, Erasmus University and Academic Hospital Dijkzigt, PO Box 1738, 3000 DR Rotterdam, The Netherlands. Fax: 31 10 463 5838.Search for more papers by this author Fritz H. Schröder, Corresponding Author Fritz H. SchröderProfessor Fritz H. Schröder, Department of Urology, Erasmus University and Academic Hospital Dijkzigt, PO Box 1738, 3000 DR Rotterdam, The Netherlands. Fax: 31 10 463 5838.Search for more papers by this author First published: August 1994 https://doi.org/10.1111/j.1365-2265.1994.tb02521.xCitations: 15AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat References Andersson, S., Berman, D.M., Jenkins, E.P. & Russell, D.W. (1992) Deletion of steroid 5 alpha-reductase 2 gene in male pseudohermaphroditism. Nature, 354, 159–161. Andersson, S., Bishop, R.W. & Russell, D.W. (1989) Expression cloning and regulation of steroid 5α reductase, an enzyme essential for male sexual differentiation. Journal of Biological Chemistry, 264, 16249–16255. Andersson, S. & Russell, D.W. (1990) Structural and biochemical properties of cloned and expressed human and rat steroid 5 alpha-reductases. Proceedings of the National Academy of Sciences, USA, 87, 3640–3644. Andriole, G., Block, N., Boake, R., Cox, C., Crawford, D., Fradet, Y., Kadmon, J., DeKernion, J., Lieber, M., Middleton, R., Patterson, J., Perreault, J., Rajfer, J., Ramsey, E., Schröder, F., Soloway, M., Smith, J., Trachtenberg, J., Ferguson, J.N.D. & Gormley, D.J. (1994) Two years of treatment with Finasteride after radical prostatectomy. Journal of Urology, 151 (5), 435A, abstr. 832. Beckmann, M.W., Wieacker, P., Dereser, M.M., Flecken, U. & Breckwoldt, M. (1993) Influence of steroid hormones on 5 alpha-reductase activity in female and male genital skin fibroblasts in culture. Acta Endocrinologica, 128, 161–167. Beisland, H.O., Binkowitz, B., Brekkan, E., Ekman, P., Kontturi, M., Lehtonen, T., Lundmo, P., Pappas, F., Round, E., Shapiro, D., Stoner, E., Swartz, R. & Varenhorst, E. (1992) Scandinavian clinical study of Finasteride in the treatment of benign prostatic hyperplasia. European Urology, 22, 271–277. Bosch, R.J.L.H., Griffiths, D.J., Blom, J.H.M. & Schröder, F.H. (1989) Treatment of benign prostatic hyperplasia by androgen deprivation: effects on prostate size and urodynamic parameters. Journal of Urology, 141, 68–72. Boudou, P., Fiet, J., Vexiau, P., Villette, J.M., Hardy, N. & Dreux, C. (1990) Greater conversion of testosterone to 5 alpha-dihydrotestosterone, reflecting increased peripheral 5 alpha-reductase activity in nude mice treated with high doses of cyclosporine A. Journal of Steroid Biochemistry, 36, 597–601. Brooks, J.R., Baptista, E.M., Berman, C., Ham, E.A., Hichens, M., Johnston, D.B.R., Primka, R.L., Rasmusson, G.H., Reynolds, G.F., Schmitt, S.M. & Arth, G.E. (1981) Response of rat ventral prostate to a new and noval 5α-reductase inhibitor. Endocrinology, 109, 830–836. Brooks, J.R., Berman, C., Games, D., Giltinan, D., Gordon, L.R., Malatesta, P.F., Primka, R.L., Reynolds, G.F. & Rasmusson, G.H. (1986) Prostatic effects induced in dogs by chronic or acute oral administration of 5α-reductase inhibitors. Prostate, 9, 65–75. Brooks, J.R., Berman, C., Nguyen, H., Prahaloda, S., Primka, R.L., Rasmussion, G.H. & Seater, E.E. (1991) Effect of castration, DES, Flutatide and the 5α-reductase inhibitor, MK-906, on the growth of the Dunning rat prostatic carcinoma, R-3327. Prostate, 18, 215–227. Clark, R.L., Anderson, C.A., Prahalada, S., Robertson, R.T., Lochry, E.A., Leonard, Y.M., Stevens, J.L. & Hoberman, A.M. (1993) Critical developmental periods for effects on male rat genitalia induced by finasteride, a 5-alpha-reductase inhibitor. Toxicology and Applied Pharmacology, 119, 34–40. Clark, R.L., Antonello, J.M., Grossman, S.J., Wise, L.D., Anderson, C., Bagdon, W.J., Prahalada, S., MacDonald, J.S. & Robertson, R.T. (1990) External genitalia abnormalities in male rats exposed in utero to finasteride, a 5 alpha-reductase inhibitor. Teratology, 42, 91–100. Cook, T., Stoner, E., Shapiro, D., Finasteride Study Group & Woodridge, N.J. (1993) Efficacy is maintained with long-term use of Finasteride with no increase in adverse experiences. Journal of Urology, 194, 431A (abstr. 875). Depre, M., Meeter, C., Hecken, A. van, Laskin, O.L., Buntinx, A. & Schepper, P.J. de (1992) Pharmacodynamics and tolerability of L-654,066, a steroid 5-alpha-reductase inhibitor in men. Clinical Pharmacology and Therapeutics, 52, 409–412. Ellison, S.A. & Pardridge, W.M. (1990) Reduction of testosterone availability to 5-alpha-reductase by human sex hormone-binding globulin in the rat ventral prostate gland in vivo. Prostate, 17, 281–291. Farmitalia Carlo Erba (1993) Investigator's Brochure: Turosteride (FCE 26073). Finasteride Study Group (1993) Finasteride (MK-906) in the treatment of benign prostatic hyperplasia. Prostate, 22, 291–299. Gaston, K. & Fried, M. (1992) The isolation of transcription factors from lambda gt11 cDNA expression libraries: human steroid 5 alpha-reductase 1 has sequence-specific DNA binding activity. Nucleic Acids Research, 20, 6297–6301. Geller, J. (1990) Effect of Finasteride, a 5α-reductase inhibitor on prostate tissue androgens and prostate-specific antigen. Journal of Clinical Endocrinology and Metabolism, 71, 1552–1555. George, F.W., Russell, D.W. & Wilson, J.D. (1991) Feed-forward control of prostate growth: dihydrotestosterone induces expression of its own biosynthetic enzyme, steroid 5 alpha-reductase. Proceedings of the National Academy of Sciences, USA, 88, 8044–8047. Gormley, G.J. (1991) Role of 5α-reductase inhibitors in the treatment of advanced prostatic carcinoma. Urologic Clinics of North America, 18, 93–98. Gormley, G.J., Stoner, E., Bruskewitz, R.C., Imperato-McGinley, J., Walsh, P.C., McConnell, J.D., Andriole, G.L., Geller, J., Bracken, B.R., Tonover, J.S., Vaughan, E.D., Pappas, F., Taylor, A., Binkowitz, B., Ng, J., for the Finasteride Group (1992) The effect of Finasteride in men with benign prostatic hyperplasia. New England Journal of Medicine, 327, 1185–1191. Griffiths, D.J., Van Mastrigt, R. & Bosch, R. (1989) Quantification of urethral resistance and bladder function during voiding, with special reference to the effects of prostate size reduction on urethral obstruction due to benign prostatic hyperplasia. Neurourology and Urodynamics, 8, 17–27. Guess, H.A., Heyse, J.F. & Gormley, G.J. (1993) The effect of Finasteride on prostate-specific antigen in men with benign prostatic hyperplasia. Prostate, 22, 31–37. Hirsch, K.S., Jones, C.D., Audia, J.E., Andersson, S., McQuaid, L., Stamm, N.B., Neubauer, B.L., Pennington, P., Toomey, R.E. & Russell, D.W. (1993) LY191704: a selective, non-steroidal inhibitor of human steroid 5α-reductase type 1. Proceedings of the National Academy of Sciences, USA, 90, 5277–5281. Imperato-McGinley, J., Gautier, T., Zirinsky, K., Hom, T., Palomo, O., Stein, E., Vaughan, E.D., Markisz, J.A., Ramirez de Arellano, E. & Kazam, E. (1992) Prostate visualization studies in males homozygous and heterozygous for 5-alpha-reductase deficiency. Journal of Clinical Endocrinology and Metabolism, 75, 1022–1026. Imperato-McGinley, J., Guerrero, L., Gautier, T. & Peterson, R. (1974). 5α-reductase deficiency in man: an inherited form of male pseudohermaphroditism. Science, 186, 1213–1215. Jenkins, E.P., Andersson, S., Imperato-McGinley, J., Wilson, J.D. & Russell, D.W. (1992) Genetic and pharmacological evidence for more than one human steroid 5 alpha-reductase. Journal of Clinical Investigation, 89, 293–300. Johnsonbaugh, R.E., Cohen, B.R., McCormack, E.M., George, F.W. & Wilson, J.D. (1993) Effect of 14 days treatment with Epristeride, an uncompetitive 5α-reductase inhibitor, on serum and prostatic testosterone (T) and dihydrotestosterone (DHT) in men with benign prostatic hyperplasia (BPH). Journal of Urology, 149, 432A (abstr. 877). Jones, C.D., Audia, J.E., Lawhorn, D.E., McQuaid, L.A., Neubauer, B.L., Pike, A.J., Pennington, P.A., Stamm, N.B., Toomey, R.E. & Hirsch, K.S. (1993) Nonsteroidal inhibitors of human type I steroid 5-alpha-reductase. Journal of Medical Chemistry, 36, 421–423. Jost, A. (1953) Problems of fetal endocrinology: the gonadal and hypophyseal hormones. Recent Progress on Hormonal Research, 8, 38–53. Lamb, J.C., English, H., Levandoski, P.L., Rhodes, G.R., Johnson, R.K. & Isaacs, J.T. (1992a) Prostatic involution in rats induced by a novel 5α-reductase inhibitor, SK&F-105657: role for testosterone in the androgenic response. Endocrinology, 130, 685–694. Lamb, J.C., Levy, M.A., Johnson, R.K. & Isaacs, J.T. (1992b) Response of rat and human prostatic cancers to the novel 5α-reductase inhibitor, SK & F-105657. Prostate, 21, 15–34. Liang, T., Cascieri, M.A., Cheung, A.H., Reynolds, G.F. & Rasmusson, G.H. (1985) Species differences in prostatic steroid 5α-reductase of rat, dog and human. Endocrinology, 117, 571–579. Liang, T., Heiss, C., Cheung, A.H., Reynolds, G.F. & Rasmusson, G.H. (1984) 4-Azasteroidal 5α-reductase inhibitors without affinity for the androgen receptor. Journal of Biological Chemistry, 259, 734–739. Liang, T. & Liao, S. (1992) Inhibition of steroid 5-alpha-reductase by specific aliphatic unsaturated fatty acids. Biochemical Journal, 285, 557–562. Liang, T., Rasmussen, G.H. & Brooks, J.R. (1983) Biochemical and biological studies with 4-Azasteroidal 5α-reductase inhibitors. Journal of Steroid Biochemistry, 19, 385–390. Lephart, E.D., Simpson, E.R. & Trzeciak, W.H. (1991) Rat adrenal 5-alpha-reductase mRNA content and enzyme activity are sex hormone-dependent. Journal of Molecular Endocrinology, 6, 163–170. McConnell, J.D. (1990) Androgen ablation and blockade in the treatment of benign prostatic hyperplasia. Urologic Clinics of North America, 17, 661–670. McConnell, J.D., Wilson, J.D., George, F.W., Geller, J., Pappas, F. & Stoner, E. (1992) Finasteride, an inhibitor of 5-alpha-reductase, suppresses prostatic dihydrotestosterone in men with benign prostatic hyperplasia. Journal of Clinical Endocrinology and Metabolism, 74, 505–508. Normington, K. & Russell, D.W. (1992) Tissue distribution and kinetic characteristics of rat steroid 5-alpha-reductase isozymes. Evidence for distribution physiological functions. Journal of Biological Chemistry, 267, 19548–19554. Oesterling, J.E., Epstein, J.I. & Walsh, P.C. (1986) The viability of adrenal androgens to stimulate the adult human prostate: an autopsy, evaluation of men with gonadotropic hypogonadism and panhypopituitarism. Journal of Urology, 136, 1030–1034. Peters, C.A. & Walsh, P.C. (1987) The effect of nafarelin acetate, a luteinizing-hormone-releasing hormone agonist, on benign prostatic hyperplasia. New England Journal of Medicine, 317, 599–604. Presti, J.C., Fair, W.R., Andriole, G., Sogani, P.C., Seidmon, E.J., Ferguson, D., Ng, J. & Gormley, G.J. (1992) Multicenter, randomized, double-blind, placebo-controlled study to investigate the effect of Finasteride (MK-906) on stage D prostate cancer. Journal of Urology, 148, 1201–1204. Prins, G.S., Cooke, P.S., Birch, L., Donjacour, A.A., Yalcinkaya, T.M., Siiteri, P.K. & Cunha, G.R. (1992) Androgen receptor expression and 5 alpha-reductase activity along the proximal-distal axis of the rat prostatic duct. Endocrinology, 130, 3066–3073. Rasmusson, G.H., Reynolds, G.F., Utne, T., Jobson, R.B., Primka, R.L., Berman, C. & Brooks, J.R. (1984) Azasteroids as inhibitors of rat prostatic 5α-reductase. Journal of Medicinal Chemistry, 27, 1690–1701. Rittmaster, R.S., Magor, K.E., Manning, A.P., Normal, R.W. & Lazier, C.B. (1991) Differential effect of 5-alpha-reductase inhibition and castration on androgen-related gene expression in rat prostate. Molecular Endocrinology, 5, 1023–1029. Rittmaster, R.S., Stoner, E., Thompson, D.L., Nance, D. & Lasseter, K.C. (1989) Effect of MK-906, a specific 5α-reductase inhibitor, on serum androgens and androgen conjugates in normal men. Journal of Andrology, 10, 259–262. Romijn, J.C. (1989) Steroid hormones, receptors and benign prostatic hyperplasia. In New Developments in Biosciences 5: Prostatic Hyperplasia—Etiology, Surgical and Conservative Management (ed. R. Ackermann & F. H. Schröder), pp. 63–72. Walter de Gruyter & Co., Berlin , New York . Salle, E. di, Briatico, G., Giudici, D., Ornati, G., Nesi, M. & Panzeri, A. (1992) Acylurea derivatives of 4-azasteroids as inhibitors of testosterone 5α-reductase. Journal of Steroid Biochemical Molecular Biology, 41, 765–768. Salle, E. di, Giudici, D., Briatico, G., Ornati, G. & Panzeri, A. (1993) Hormonal effects of Turosteride, a 5α-reductase inhibitor, in the rat. Journal of Steroid Molecular Biology, 46, 549–555. Scott, W.W. (1953) What makes the prostate grow. Journal of Urology, 70, 477–479. Schröder, F.H., Westerhof, M., Bosch, R.J.L.H. & Kurth, K.H. (1986) Benign prostatic hyperplasia treated by castration or the LH-RH analogue buserelin: a report on 6 cases. European Urology, 12, 318–321. Siiteri, P.K. & Wilson, J.D. (1970) The formation and content of dihydrotestosterone in the hypertrophic prostate of man. Journal of Clinical Investigation, 49, 1737–1745. Sneller, Z.W., Hop, W.C.J., Carpentier, P.J. & Schröder, F.H. (1992) Prognosis and prostatic volume changes during endocrine management of prostate cancer: a longitudinal study. Journal of Urology, 147, 962–966. Stone, N.N. (1989) Flutamide in treatment of benign prostatic hypertrophy. Urology, 34 (Suppl. 4), 64–68. Stoner, E. (1992) The clinical effects of 5α-reductase inhibitor, Finasteride, on benign prostatic hyperplasia. The Finasteride Study Group. Journal of Urology, 147, 1298–1302. Tempany, C.M., Partin, A.W., Zerhouni, E.A., Zinreich, S.J. & Walsh, P.C. (1993) The influence of Finasteride on the volume of the peripheral and periurethral zones of the prostate in men with benign prostatic hyperplasia. Prostate, 22, 39–42. Thigpen, A.E., Davis, D.L., Milatovich, A., Mendonca, B.B., Imperato-McGinley, J., Griffin, J.E., Francke, U., Wilson, J.D. & Russell (1992a) Molecular genetics of steroid 5 alpha-reductase 2 deficiency. Journal of Clinical Investigation, 90, 799–809. Thigpen, A.E., Silver, R.I., Guileyardo, J.M., Casey, M., McConnell, J.D. & Russell, D.W. (1992b) Tissue distribution and ontogeny of steroid 5α-reductase isozyme expression. Journal of Clinical Investigation, 92, 903–910. Vermeulen, A., Giagulli, V.A., Schepper, P. de, Buntinx, A. & Stoner, E. (1989) Hormonal effects of an orally active 4-azasteroid inhibitor of 5α-reductase in humans. Prostate, 14, 45–53. Walsh, P.C., Madden, J.D., Harrod, M.J., Goldstein, J.L., MacDonald, P.C. & Wilson, J.D. (1974) Familial incomplete male pseudohermaphroditism, type 2: decreased dihydrotestosterone formation is pseudovaginal perineoscrotal hypospadias. New England Journal of Medicine, 291, 944. Walsh, P.C., Hutchins, G.M. & Ewing, L.L. (1983) Tissue content of dihydrotestosterone in human prostatic hyperplasia is not supranormal. Journal of Clinical Investigation, 72, 1772–1777. Wilson, J.D. (1989) Sexual differentiation of the gonads and of the reproductive tract. Biology of the Neonate, 55, 322–330. Citing Literature Volume41, Issue2August 1994Pages 139-147 ReferencesRelatedInformation
Referência(s)